Axsome Therapeutics (AXSM) Gets a Buy Rating from Berenberg Bank

In a report released today, Esther Hong from Berenberg Bank maintained a Buy rating on Axsome Therapeutics (AXSMResearch Report), with a price target of $109.00. The company’s shares closed last Thursday at $44.20.

According to, Hong ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -17.7% and a 27.2% success rate. Hong covers the Healthcare sector, focusing on stocks such as Cerevel Therapeutics Holdings, ACADIA Pharmaceuticals, and Aldeyra Therapeutics.

Currently, the analyst consensus on Axsome Therapeutics is a Strong Buy with an average price target of $87.57, which is an 86.9% upside from current levels. In a report issued on March 29, BTIG also maintained a Buy rating on the stock with a $62.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $74.10 and a one-year low of $19.38. Currently, Axsome Therapeutics has an average volume of 710.2K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. Its product candidates include AXS-02 and AXS-06 which are developing for multiple indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Read More on AXSM:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More